SkinBioTherapeutics ( (GB:SBTX) ) has shared an announcement.
SkinBioTherapeutics plc announced the exercise of warrants by Macquarie for 1,000,000 ordinary shares at £0.2043 per share, leaving 1,099,244 warrants outstanding. Following this exercise, the company’s total issued shares and voting rights will increase to 232,975,383, impacting shareholder calculations under the Financial Conduct Authority’s rules.
More about SkinBioTherapeutics
SkinBioTherapeutics is a life science company focused on skin health, utilizing its proprietary platform technology, SkinBiotix®, developed from research at the University of Manchester. The company targets the skin healthcare market through five pillars, with a focus on cosmetic skincare and food supplements that modulate the immune system. It has partnerships and is expanding through acquisitions to enhance its distribution and manufacturing capabilities.
YTD Price Performance: 35.14%
Average Trading Volume: 805,041
Technical Sentiment Signal: Sell
Current Market Cap: £56.83M
See more insights into SBTX stock on TipRanks’ Stock Analysis page.